Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis,Immunity, Inflammation and Disease

当前位置： X-MOL 学术 › Immun. Inflamm. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis
Immunity, Inflammation and Disease ( IF 2.493 ) Pub Date : 2021-09-16 , DOI: 10.1002/iid3.534
Lina Lin ₁ , Weixia Nong _{1,

2} , Bin Luo _{1,

2} , Yingying Ge _{1,

2} , Xia Zeng ₁ , Feng Li ₁ , Rong Fan ₃ , Qingmei Zhang _{1,

2} , Xiaoxun Xie _{1,

2}

Affiliation

Cancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian cancer (OC).

中文翻译：